Leap Therapeutics reports 30% ORR and 93% DCR in Part A of DeFianCe study for DKN-01 in second-line CRC

CYPHERPUNK TECHNOLOGIES INC.

Across 27 evaluable microsatellite stable CRC patients: ORR 30%, DCR 93%, median PFS 6.3 months.
Left-sided tumors: 33% ORR, 100% DCR, preliminary median PFS 8.6 months.
Rectal/rectosigmoid subgroup (n=15): 46% ORR, 100% DCR, preliminary median PFS 9.4 months.
DKN-01 plus bevacizumab and chemotherapy well-tolerated; majority of related events Grade 1/2.
Part B of study enrolling well, expected to complete enrollment mid-2024; conference call January 23.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.